These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

195 related items for PubMed ID: 37341961

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis.
    van de Kerkhof PC, Griffiths CE, Reich K, Leonardi CL, Blauvelt A, Tsai TF, Gong Y, Huang J, Papavassilis C, Fox T.
    J Am Acad Dermatol; 2016 Jul; 75(1):83-98.e4. PubMed ID: 27180926
    [Abstract] [Full Text] [Related]

  • 3. Efficacy of Secukinumab Across Subgroups and Overall Safety in Pediatric Patients with Moderate to Severe Plaque Psoriasis: Week 52 Results from a Phase III Randomized Study.
    Magnolo N, Kingo K, Laquer V, Browning J, Reich A, Szepietowski JC, Keefe D, Papanastasiou P, Bao W, Forrer P, Patekar M.
    Paediatr Drugs; 2022 Jul; 24(4):377-387. PubMed ID: 35698000
    [Abstract] [Full Text] [Related]

  • 4. Secukinumab demonstrates high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis: 52-week results from a Phase 3 double-blind randomized, controlled trial.
    Bodemer C, Kaszuba A, Kingo K, Tsianakas A, Morita A, Rivas E, Papanastasiou P, Keefe D, Patekar M, Charef P, Zhang L, Cafoncelli S, Papavassilis C.
    J Eur Acad Dermatol Venereol; 2021 Apr; 35(4):938-947. PubMed ID: 33068444
    [Abstract] [Full Text] [Related]

  • 5. Secukinumab long-term efficacy and safety in psoriasis through to year 5 of treatment: results of a randomized extension of the phase III ERASURE and FIXTURE trials.
    Langley RG, Sofen H, Dei-Cas I, Reich K, Sigurgeirsson B, Warren RB, Paul C, Szepietowski JC, Tsai TF, Hampele I, You R, Charef P, Papavassilis C.
    Br J Dermatol; 2023 Feb 10; 188(2):198-207. PubMed ID: 36763857
    [Abstract] [Full Text] [Related]

  • 6. Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data.
    Deodhar A, Mease PJ, McInnes IB, Baraliakos X, Reich K, Blauvelt A, Leonardi C, Porter B, Das Gupta A, Widmer A, Pricop L, Fox T.
    Arthritis Res Ther; 2019 May 02; 21(1):111. PubMed ID: 31046809
    [Abstract] [Full Text] [Related]

  • 7. Secukinumab in plaque psoriasis--results of two phase 3 trials.
    Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CE, Papp K, Puig L, Nakagawa H, Spelman L, Sigurgeirsson B, Rivas E, Tsai TF, Wasel N, Tyring S, Salko T, Hampele I, Notter M, Karpov A, Helou S, Papavassilis C, ERASURE Study Group, FIXTURE Study Group.
    N Engl J Med; 2014 Jul 24; 371(4):326-38. PubMed ID: 25007392
    [Abstract] [Full Text] [Related]

  • 8. Safety of guselkumab treatment for up to 5 years in patients with moderate-to-severe psoriasis: pooled analyses across seven clinical trials with more than 8600 patient-years of exposure.
    Lebwohl MG, Merola JF, Rowland K, Miller M, Yang YW, Yu J, You Y, Chan D, Thaçi D, Langley RG.
    Br J Dermatol; 2023 Jul 07; 189(1):42-52. PubMed ID: 37022762
    [Abstract] [Full Text] [Related]

  • 9. A phase 3 open-label, randomized multicenter study to evaluate efficacy and safety of secukinumab in pediatric patients with moderate to severe plaque psoriasis: 24-week results.
    Magnolo N, Kingo K, Laquer V, Browning J, Reich A, Szepietowski JC, Keefe D, Mazur R, Ghelani P, Forrer P, Wraith L, Patekar M.
    J Am Acad Dermatol; 2022 Jan 07; 86(1):122-130. PubMed ID: 34555481
    [Abstract] [Full Text] [Related]

  • 10. Safety of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials.
    Blauvelt A, Reich K, Papp KA, Kimball AB, Gooderham M, Tyring SK, Sinclair R, Thaçi D, Li Q, Cichanowitz N, Green S, La Rosa C.
    Br J Dermatol; 2018 Sep 07; 179(3):615-622. PubMed ID: 29742274
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Secukinumab: A Review in Moderate to Severe Pediatric Plaque Psoriasis.
    Blair HA.
    Paediatr Drugs; 2021 Nov 07; 23(6):601-608. PubMed ID: 34665445
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Bimekizumab safety in patients with moderate-to-severe plaque psoriasis: pooled data from up to 3 years of treatment in randomized phase III trials.
    Gordon KB, Langley RG, Warren RB, Okubo Y, Rosmarin D, Lebwohl M, Peterson L, Madden C, de Cuyper D, Davies O, Thaçi D.
    Br J Dermatol; 2024 Mar 15; 190(4):477-485. PubMed ID: 37950894
    [Abstract] [Full Text] [Related]

  • 16. Long-term Efficacy and Safety of Up to 108 Weeks of Ixekizumab in Pediatric Patients With Moderate to Severe Plaque Psoriasis: The IXORA-PEDS Randomized Clinical Trial.
    Paller AS, Seyger MMB, Magariños GA, Pinter A, Cather JC, Rodriguez-Capriles C, Zhu D, Somani N, Garrelts A, Papp KA, IXORA-PEDS Investigators.
    JAMA Dermatol; 2022 May 01; 158(5):533-541. PubMed ID: 35416908
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Meta-analysis of the Efficacy and Safety of Secukinumab for the Treatment of Plaque Psoriasis.
    Ryoo JY, Yang HJ, Ji E, Yoo BK.
    Ann Pharmacother; 2016 May 01; 50(5):341-51. PubMed ID: 26783352
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and Safety of Secukinumab in Elderly Subjects with Moderate to Severe Plaque Psoriasis: A Pooled Analysis of Phase III Studies.
    Körber A, Papavassilis C, Bhosekar V, Reinhardt M.
    Drugs Aging; 2018 Feb 01; 35(2):135-144. PubMed ID: 29404966
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and Safety of Brodalumab in Patients with Moderate-to-Severe Plaque Psoriasis and Skin of Color: Results from the Pooled AMAGINE-2/-3 Randomized Trials.
    McMichael A, Desai SR, Qureshi A, Rastogi S, Alexis AF.
    Am J Clin Dermatol; 2019 Apr 01; 20(2):267-276. PubMed ID: 30471012
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.